NEWSROOM
Press Releases by Agendia
News
Press Releases
Agendia Level 1B Evidence Shows MammaPrint is the First and Only FDA-cleared Gene Expression Profiling Test to Predict Benefit from Extended Endocrine Therapy in Early-Stage Breast Cancer Patients
Late-breaking abstract at the 2022 San Antonio Breast Cancer Symposium (SABCS) will illustrate MammaPrintโs ability to identify strongest candidates for extended endocrine therapy among HR+HER2- post-menopausal women December 08, 2022 09:00 AM Eastern Standard Time Read More
Level One Evidence Proves Premenopausal Patients within the Ultra-Low Subset of Agendiaโs MammaPrint Low Risk Result Can Safely Forgo Chemotherapy
MammaPrint is the only FDA-cleared gene expression test to identify early breast cancer tumors with an Ultra-Low risk that can safely avoid chemotherapy, with a 99% breast cancer specific survival (BCSS) and 97% distant metastasis Read More
Agendia Spotlights the Future of Personalized Breast Cancer Care at 2022 San Antonio Breast Cancer Symposium
Demonstrates the ongoing impact of its 10,000-patient FLEX trial to fuel breast cancer research and produce practice-changing results All six presentations will emphasize how MammaPrintยฎ and BluePrintยฎ empower personalized, proactive treatment decisions with test results Read More
Agendia Announces First Patient Enrolled in Prospective LESS Clinical Study, Sponsored by Unicancer, to De-escalate Endocrine Therapy in Women with Early Breast Cancer
The LESS study will evaluate reduced endocrine therapy for HR+/HER2- patients with MammaPrintยฎ Ultra Low tumors to improve quality of life without compromising outcomes Study strengthens Agendiaโs growing global footprint in breast cancer to inform Read More
Agendia Presents Data from the FLEX Real World Evidence Trial in Seven Posters at ASCO 2022, Showcasing the Power of Its 30,000-Patient Breast Cancer Genome Project
Data show MammaPrintยฎย is the first and most comprehensive FDA-cleared test for early breast cancer resulting in the ability to identify women who may be over- or under-treated if treatment decisions relied on the 21-gene assay Read More
Agendia Presents Data at ASCO 2022 Pointing to New Signature ImPrint Immunotherapy Prediction and Expansion of Proprietary Genomic Testsโ Utility to Identify Patients Who Will Benefit Most from Specific Treatments
Data demonstrate Research Use Only ImPrint testโs ability to identify patients with high risk early breast cancer who may benefit from PD-1/PD-L1 checkpoint inhibition IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS - June 4, 2022 โ Read More
Agendia Achieves Historic Milestone of Enrolling 10,000 Patients in FLEX, the Largest-Ever Prospective, Real-World-Evidence Trial for Patients With Early Stage Breast Cancer
Company to present multiple recent Registry sub-studies driving cancer care innovation at ASCO 2022 IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ May 25, 2022 โ Agendia, Inc., a commercial-stage company focused on improving outcomes for Read More
